Zheng Xiao

Zheng Xiao

Auto-generated profile, based on publicly available information

Zheng Xiao

Evidence-Based Medicine Center, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563003, China.

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 March 2020 in Pharmacological Research
Verified
Journal Article
Closed access
ZXZheng Xiao
Zheng Xiao
YJYuan Jiang
Yuan Jiang
CWCheng-Qiong Wang
Cheng-Qiong Wang
SHShan-Shan Hu
Shan-Shan Hu
XHXiao-Rong Huang
Xiao-Rong Huang
XLXiaofei Li
Xiaofei Li

23 June 2018 in International Immunopharmacology
Verified
Journal Article
Closed access
ZXZheng Xiao
Zheng Xiao
CWCheng-Qiong Wang
Cheng-Qiong Wang
MZMing-Hua Zhou
Ming-Hua Zhou
NLNa-Na Li
Na-Na Li
SLShi-Yu Liu
Shi-Yu Liu
JDJie Ding
Jie Ding

28 May 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
CWCheng-Qiong Wang
Cheng-Qiong Wang
XZXiao-Tian Zheng
Xiao-Tian Zheng
XCXiao-Fan Chen
Xiao-Fan Chen
HJHong Jiang
Hong Jiang
JHJun Huang
Jun Huang
ZXZheng Xiao
Zheng Xiao
Introduction: Aidi injection (Aidi) is composed of cantharidin, astragaloside, ginsenoside, and elentheroside E. As an important adjuvant therapy, Aidi in combination with gemcitabine and cisplatin (GP) is often used in the treatment of non-small cell lung cancer (NSCLC).Objectives: We performed a new evaluation to demonstrate the clinical efficacy and safety of the Aidi and GP combination and further explored an optimal strategy for achieving an ideal response and safety level in advanced NSCLC.Methodology: We collected all the related trials from Chinese and English-language databases, analyzed their methodological bias risk using the Cochrane evaluation Handbook for Systematic Reviews of Interventions Version 5.1.0, extracted all the data using a predefined data extraction form, pooled the data using a series of meta-analyses, and finally summarized the quality of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.Results: We included 70 trials with 5,509 patients. Compared with GP alone, the Aidi and GP combination showed a significant improvement in the objective response rate (ORR) [1.82 (1.62–2.04)], disease control rate (DCR) [2.29 (1.97–2.67)], and quality of life (QOL) [3.03 (2.55–3.60)] and a low incidence of hematotoxicity and gastrointestinal and hepatorenal toxicity. Aidi might be more suitable for patients who are first-treated, elderly, or patients with a Karnofsky Performance Status (KPS) score ≥ 60 or anticipated survival time (AST) ≥3 months. An Aidi (50 ml/day, 7–14 days/cycle for one to two cycles), gemcitabine (1000 mg/m2), and cisplatin (20–30 mg/m2, 40–50 mg/m2, or 60–80 mg/m2) might be an optimal regimen for realizing an ideal response and safety level. Most results were robust and of moderate quality.Conclusion: Current evidence indicates that Aidi's value in adjuvant chemotherapy may be broad-spectrum, not just for some regimens. The Aidi and GP combination may show a good short-term response, antitumor immunity, and safety level in patients with NSCLC. Aidi (50 ml/day, 7–14 days/cycle for one and two cycles) with GEM (1000 mg/m2) and DDP (20–30 mg/m2 or 40–50 mg/m2) may be an optimal regimen for realizing an ideal goal in patients who are first-treatment, elderly, or have a KPS score ≥ 60 or AST≥3 months.

1 April 2018 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
ZXZheng Xiao
Zheng Xiao
CWChengqiong Wang
Chengqiong Wang
RZRui Zhou
Rui Zhou
SHShanshan Hu
Shanshan Hu
NYNian Yi
Nian Yi
XLXiaofei Li
Xiaofei Li

25 November 2016 in Oncotarget
Verified
Journal Article
Open access
ZXZheng Xiao
Zheng Xiao
CWChengqiong Wang
Chengqiong Wang
LCLing Chen
Ling Chen
XTXuemei Tang
Xuemei Tang
LLLianhong Li
Lianhong Li
XLXiaofei Li
Xiaofei Li
Has aidi injection the attenuation and synergistic efficacy to gemcitabine and cisplatin in non-small cell lung cancer? A meta-analysis of 36 randomized controlled trials